STEPHANIE KEILEN: Open Payments
NPI 1518399484 · CHARLOTTE, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$455 in 22 payments from 14 companies in 2025. Trend: 2023 $160 · 2024 $442 · 2025 $455
Food & beverage: $455
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $108 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| Novo Nordisk Inc | 2 | $48 |
| Eisai Inc. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| AstraZeneca Pharmaceuticals LP | 2 | $33 |
| Alkermes, Inc. | 1 | $29 |
| PFIZER INC. | 1 | $21 |
| GlaxoSmithKline, LLC. | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
Products named: REXULTI, Auvelity, Leqembi, CAPLYTA, AIRSUPRA, VIVITROL, ABILIFY MAINTENA, Ozempic.
Industry payments across MI — which companies pay providers there.
